The generic name for Stendra is avanafil [1].
When is the Stendra (avanafil) patent expected to expire?
The principal patent for avanafil, U.S. Patent No. 8,097,631, is set to expire in 2028 [2]. However, there are additional patents and potential patent term extensions that could affect the timeline for generic entry [2].
What other medications are available for erectile dysfunction?
Other medications used to treat erectile dysfunction include sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) [3]. These drugs belong to the same class as avanafil, phosphodiesterase type 5 (PDE5) inhibitors, and work by increasing blood flow to the penis [3].
How do avanafil and sildenafil compare?
Avanafil is a PDE5 inhibitor, as is sildenafil. Clinical studies have shown that avanafil can be effective in treating erectile dysfunction, with some research suggesting a faster onset of action compared to other PDE5 inhibitors [4].
What are the risks and side effects associated with avanafil?
Common side effects of avanafil include headache, flushing, nasal congestion, and back pain [1]. Serious side effects are rare but can include sudden vision loss or a prolonged erection lasting more than four hours [1]. It is important for individuals to consult a healthcare provider to discuss potential risks and suitability for use [1].
Can generic avanafil be produced before the patent expires?
The ability to produce generic avanafil before the patent expiration date would depend on the outcome of any patent litigation or the specific terms of any licensing agreements [2]. Companies often challenge patents to seek earlier market entry for generic versions.